Anti-CD24 Nano-targeted Delivery of Docetaxel for the Treatment of Prostate Cancer

• Published in: Nanomedicine Vol. 13; no. 1; pp. 263 - 273
• Main Authors: Bharali, Dhruba J., PhD, Sudha, Thangirala, PhD, Cui, Huadong, PhD, MD, Mian, Badar M., MD, Mousa, Shaker A., PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2017
• Subjects: Animals; Anti-CD24; CD24 Antigen - chemistry; Docetaxel; Drug Delivery Systems; Internal Medicine; Lactic Acid - chemistry; Male; Mice; Mice, Nude; Nanoparticles - chemistry; PLGA nanoparticle; Polyglycolic Acid - chemistry; Prostate cancer; Prostatic Neoplasms - drug therapy; Targeted therapy; Taxoids - administration & dosage; Taxoids - therapeutic use; dynamic laser light scattering; NP; Targeted therapy; PLGA nanoparticle; Docetaxel; s.c; nanoparticle; DLS; in vivo imaging system; subcutaneous; PLGA-PEG; Anti-CD24; IVIS; poly(lactide-co-glycolide)-polyethylene glycol; Prostate cancer
• ISSN: 1549-9634; 1549-9642
• DOI: 10.1016/j.nano.2016.08.017

Abstract Nanoparticle (NP)-mediated, noninvasively targeted and image-guided therapies have potential to improve efficacy and safety of cancer therapeutics. We report synthesis and use of poly(lactide-co-glycolide)-polyethylene glycol (PLGA-PEG) NPs for targeted delivery of docetaxel. We synthesized docetaxel encapsulated NPs conjugated to anti-CD24 (for targeting) and/or an optical probe (for tracking) and evaluated efficacy in a prostate cancer mouse model. We observed preferential accumulation of anti-CD24 conjugated NPs (encapsulating docetaxel) compared to the non-conjugated NPs 24 hours after a single injection into luciferase-expressing PC3M prostate cancer tumor. In the same mouse model, we found significant ( P < 0.01) accumulation of docetaxel (~10-fold higher) in tumor after treatment with PLGA-PEG NPs encapsulating docetaxel and conjugated to anti-CD24 compared to non-conjugated NPs. Enhanced accumulation was associated with reduced tumor mass and tumor viability. These data support the potential impact of nano-targeted delivery of chemotherapy in enhancing the differential tumor delivery and anticancer efficacy in prostate cancer.